Remember meForgot password?
    Log in with Twitter
| Press Release

Wired News – Imprimis Pharma Launched New Program for Custom Compounded Ophthalmic Medications

Stock Monitor: Akcea Therapeutics Post Earnings Reporting

LONDON, UK / ACCESSWIRE / March 08, 2018 / has just released a free research report on Imprimis Pharma, Inc. (NASDAQ: IMMY). If you want access to this report all you need to do is sign up now by clicking the following link as the Company's latest news hit the wire. On March 06, 2018, the Company announced that it has launched a new program to provide ophthalmologists and optometrists with custom compounded ophthalmic medications, that are needed on an urgent basis and are increasingly difficult to find. Register today and get access to over 1,000 Free Research Reports by joining our site below: is currently working on the research report for Akcea Therapeutics, Inc. (NASDAQ: AKCA), which also belongs to the Healthcare sector as the Company Imprimis Pharma. Do not miss out and become a member today for free to access this upcoming report at: is focused on giving you timely information and the inside line on companies that matter to you. This morning, Imprimis Pharma most recent news is on our radar and our team decided to put out a fantastic report on the company that is now available for free below:

The purpose of the program is to provide high-quality compounded medications from an Imprimis Pharma FDA-inspected facility and to ship it within 24-48 hours. The program will be made available in all 50 US states. Physicians can order custom compounded formulations on an as needed basis for their patients.

Imprimis Pharma's Mission is to Make Innovative Medications Accessible and Affordable for Patients

Mark L. Baum, Chief Executive Officer of Imprimis Pharma, stated that the mission of the Company is to make innovative medications accessible and affordable for patients. Mark added that as a partner to thousands of eye care professionals and in furtherance of Imprimis Pharma's corporate mission, the Company is pleased to now make these critical medications available.

Imprimis Pharma Received DEA Manufacturer Certificate for 503B Outsourcing Facility

On January 24, 2018, the Company announced that following inspection by the US Drug Enforcement Administration, its New Jersey FDA-registered outsourcing facility was issued a DEA Manufacturer Controlled Substance Registration Certificate. This registration further allowed Imprimis Pharma to leverage its national compounding platform and its relationships with nearly 2,000 ophthalmology and optometric customers, including many of the largest ambulatory surgery centers in the US and numerous hospital systems, in order to provide patients and their healthcare professionals with affordable compounded formulations. Under the authority of the Controlled Substances Act of 1970, the Drug Enforcement Administration (DEA), Office of Diversion Control (OD) regulates the manufacture and distribution of controlled substances in the US.

In February 2017, Imprimis Pharma begun shipping its core sterile ophthalmic medications to select customers from its FDA-registered New Jersey outsourcing facility without the need for a patient-specific prescription. The Company's 503B outsourcing facility is equipped with robotics for automated filling and labeling of products.

Imprimis Pharma's Approach of Making Drugs Affordable Through Innovative Technology

The Company is pioneering a new commercial pathway in the pharmaceutical industry, using compounding pharmacies for the formulation and distribution of high quality, proprietary, compounded formulations at affordable prices. Imprimis Pharma partners with healthcare providers and pharmacy benefit managers to ensure high quality medications at affordable prices for the patients. The Company's pharmacies are accredited by the Pharmacy Compounding Accreditation Board (PCAB) and operate under the regulatory framework of the Drug Quality & Security Act (2013) and state pharmacy laws. The Company specializes in customizing medications to meet unique patient and practitioner needs.

About Imprimis Pharmaceuticals, Inc.

Founded in 2012, Imprimis Pharma is a specialty pharmaceutical company focused on the development and commercialization of proprietary and novel sterile and topical drug formulations. Headquartered in San Diego, California, the Company owns and operates production and dispensing facilities located in California and New Jersey.

Stock Performance Snapshot

March 07, 2018 - At Wednesday's closing bell, Imprimis Pharma's stock rose 1.48%, ending the trading session at $2.06.

Volume traded for the day: 111.70 thousand shares.

Stock performance in the last month – up 22.62%; previous three-month period – up 16.38%; past six-month period – up 13.81%; and year-to-date - up 21.18%

After yesterday's close, Imprimis Pharma's market cap was at $40.21 million.

The stock is part of the Healthcare sector, categorized under the Biotechnology industry. This sector was up 0.5% at the end of the session.


Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

A-I has not been compensated; directly or indirectly; for producing or publishing this document.


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.


A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit


For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:


Phone number: 73 29 92 6381

Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active-Investors

Latest News
Top News